Roivant Sciences Ltd.
For the period ended Mar 31, 2026. Filed May 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed May 20, 2026
ROIV$41.19+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Roivant Sciences Ltd.Index | |
|---|---|
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 42) | 155 |
| Consolidated Financial Statements | |
| Consolidated Balance Sheets as of March 31, 2026 and 2025 | 158 |
| Consolidated Statements of Operations for the Years Ended March 31, 2026, 2025 and 2024 | 159 |
| Consolidated Statements of Comprehensive (Loss) Income for the Years Ended March 31, 2026, 2025 and 2024 | 160 |
| Consolidated Statements of Shareholders’ Equity for the Years Ended March 31, 2026, 2025 and 2024 | 161 |
| Consolidated Statements of Cash Flows for the Years Ended March 31, 2026, 2025 and 2024 | 162 |
| Notes to Consolidated Financial Statements | 163 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.